🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesNNT for MACE prevention — need advice Page 2

NNT for MACE prevention — need advice

MounjBrad Fri, Feb 13, 2026 at 10:36 PM 13 replies 976 viewsPage 2 of 3
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Feb 14, 2026 at 10:04 AM#6
MounjBrad said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

11 months later: down 38 lbs, off lisinopril, A1C from 7.6% to 5.5%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: Feb 14, 2026 at 12:04 PM
39 17fiona_VT, denise_HTX, raj_cambridge and 36 others
Reply Quote Save Share Report
ChrisMacros
Member
567
2,345
Sep 2024
Michigan
Feb 14, 2026 at 2:36 PM#7

Following on from chris_chi24 — and this may be the naive question:

How long did you give it before you decided it was working?

40 18TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 37 others
Reply Quote Save Share Report
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Feb 14, 2026 at 7:08 PM#8
DanielChem_CHI said:
I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 52 pg/mL (normal, cardiac function preserved)
  • Lp(a): 42 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 157 to 92 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

41 19DataDave, Dr.GutHealth, amsterdam_pete and 38 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
MounjBrad
Member
278
890
Oct 2024
Kentucky
Feb 14, 2026 at 11:39 PM#9
DanielChem_CHI said:
I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
42 20pam_columbus, nick_SD_fit, ben_calgary and 39 others
Reply Quote Save Share Report
CanadaChris
Member
234
890
Nov 2024
Toronto, CA
Feb 15, 2026 at 9:21 PM#10
PharmacoVig_BOS said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.
PharmacoVig_BOS said:
...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

Last edited: Feb 16, 2026 at 3:21 AM
10 10lori_vegas, Dr.PulmRoch, maya_sedona and 7 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register